3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Unknown
4
Withdrawn
1
Completed
1
Sponsor Class
OTHER
3
OTHER_GOV
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Breast Neoplasms
11
Colorectal Neoplasms
3
Carcinoma, Hepatocellular
3
Uterine Cervical Neoplasms
2
Vomiting
1
Ulcer
1
Stomatitis
1
Skin Cancer Face
1
Recurrence
1
Pathologic Complete Response
1
Parasomnias
1
Pain, Intractable
1
Ovarian Neoplasms
1
Opportunistic Infections
1
Neoplasm Metastasis
1
Nausea
1
Melanoma
1
Medulloblastoma
1
Lung Neoplasms
1
Leukemia, Myeloid, Accelerated Phase
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Kidney Neoplasms
1
Inflammation
1
Hepatitis C, Chronic
1
Hepatitis C
1
Hematologic Neoplasms
1
Glioblastoma
1
Fatigue
1
Esophageal Neoplasms
1
Epstein-Barr Virus Infections
1
Interventions
dolutegravir
1
Ritonavir
1
Nucleosides
1
Darunavir
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
OTHER_GOV
×
Acquired Immunodeficiency Syndrome
×
Clear all
NCT04183738
2020-11-10
i2-D²EFT
Kirby Institute
Phase 4
Withdrawn